secwatch.observer — SEC 8-K summary
======================================

Issuer:     QuidelOrtho Corp (QDEL)
CIK:        0001906324
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001906324-23-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QuidelOrtho Q4 2022 preliminary revenue $853-868M; non-COVID rev up 18% proforma constant currency
--------------------------------------------------------------------------------

- Preliminary Q4 total revenue $853M-$868M; COVID $124M-$134M; non-COVID $729M-$734M.
- Non-COVID product revenue grew 485% GAAP, 18% proforma constant currency; driven by strong respiratory season.
- Full year 2022 total revenue $4,038M-$4,053M; non-COVID $2,597M-$2,602M (11% proforma constant currency growth).
- CEO Doug Bryant cited growth across Molecular Diagnostics, Transfusion Medicine, and Point of Care units.
- Full earnings results and conference call scheduled for February 15, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/0001906324-23-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1906324/000190632423000002/qdel-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001906324-23-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer